CYRAMZA 10 mg/ml Injection 50 ml Vial - Precision Cancer Treatment

CYRAMZA (Ramucirumab) 10 mg/ml Injection is a specialized prescription medication developed to target and treat certain advanced cancers. This potent therapy works by inhibiting angiogenesis, the process by which new blood vessels form to supply tumors with nutrients and oxygen, thereby helping to slow tumor growth and progression.

Originally referenced on leading pharmaceutical platforms like and other e-commerce sites such as and , CYRAMZA is a critical component in comprehensive oncology care strategies.

Benefits of Use:

• Targets vascular endothelial growth factor receptor 2 (VEGFR2), crucial for tumor angiogenesis.
• Approved for the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and hepatocellular carcinoma.
• Designed to extend survival and improve disease control in eligible patients with specific advanced cancers.
• Administered as part of a carefully monitored treatment regimen by healthcare professionals.

How to Use:

1. CYRAMZA is intended for intravenous infusion only and must be administered by a qualified healthcare professional in a clinical setting.
2. The specific dosage, duration, and frequency of treatment will be determined by your physician based on your cancer type, overall health, and response to therapy.
3. The medication will be diluted before infusion and administered slowly over a prescribed period, typically 30 to 60 minutes.
4. Regular monitoring for side effects and treatment efficacy will be conducted by your medical team throughout the course of therapy.
5. Do not attempt to self-administer this medication.

Caution & Warnings:

• Serious Hemorrhage: Increased risk of severe bleeding, including fatal events. Monitor for signs and symptoms of hemorrhage.
• Gastrointestinal Perforation: Risk of gastrointestinal perforation, which can be life-threatening. Discontinue if perforation occurs.
• Arterial Thromboembolic Events: Increased risk of serious arterial clotting events (e.g., heart attack, stroke).
• Hypertension: May cause or worsen high blood pressure. Monitor blood pressure regularly and manage as needed.
• Proteinuria: Risk of significant protein in the urine, indicating kidney problems. Regular urine protein monitoring is required.
• Impaired Wound Healing: Can interfere with wound healing. Treatment should be withheld prior to surgery and not restarted until wounds are fully healed.
• Infusion-Related Reactions: Monitor for hypersensitivity reactions during and after infusion.
• Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential to use effective contraception.
• Strictly for prescription use and administration under medical supervision.
• Keep out of reach of children.

Ingredients:

• Active Ingredient: Ramucirumab 10 mg/ml
• Excipients: Histidine, polysorbate 80, water for injection, and other inactive ingredients.

Product Details:

• Brand: CYRAMZA
• Manufacturer: Eli Lilly and Company
• Dosage Form: Solution for Injection
• Strength: 10 mg/ml
• Package Size: 50 ml single-dose vial
• Storage: Store refrigerated between 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.